Immunologic monitoring and immunotherapy in Ewing's sarcoma

Richardson, Ronald L.; Oldham, Robert K.; Pomeroy, Thomas C.; Weese, James L.; McCoy, J. L.; Cannon, Grace B.; Dean, Jack H.; Herberman, Ronald B.

doi:10.1007/bf00200108

Cited by 3 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before treatment, most patients were reactive to mumps and streptococcus skin test antigens. During and after treatment, patients with poor skin test reac tivity or decreased numbers of rosette-forming lympho cytes relapsed [8]. Skin test reactivity to tumor cell extract was not different for disease-free or relapsing patients.…”

Section: Discussionmentioning

confidence: 92%

“…Scarification of BCG converted PPD-negative patients but without improving response to conventional therapy; BCG and immunization with allogeneic tumor cells failed to lengthen the survival of patients with metastatic dis ease. Of patients treated for localized disease with the conventional regimen, 4 of 5 remained tumor-free when BCG was added; and 1 of 9 remained tumor-free when BCG was not used [8]. Thus, nonspecific immunostimulation with BCG (or better standardized prepara tions) and tumor-specific immunization with cell mem branes (or 'viral oncolysates') of cultured allogeneic or autologous Ewing sarcoma cells should be investigated in view of some successes reported in the case of soft tissue sarcomas [14], Interferon acts as a cell growth regulator and it has been applied for the treatment of human osteosarcoma and lymphoma (for review, see Sinkovics [15]).…”

Section: Discussionmentioning

confidence: 99%

“…Skin test reactivity to tumor cell extract was not different for disease-free or relapsing patients. Tumor extracts elicited migration inhibitory reaction often in patients with tumor; tumor-free pa- tients often gave negative reaction [8]. Scarification of BCG converted PPD-negative patients but without improving response to conventional therapy; BCG and immunization with allogeneic tumor cells failed to lengthen the survival of patients with metastatic dis ease.…”

Section: Discussionmentioning

confidence: 99%

“…Current established treatment regimens for Ewing sar coma of primary presentation include radiotherapy to the primary site for the full length of long bones and in doses in excess of 5,000 R (up to 7,000 R) and ad juvant chemotherapy with various combinations of vincristine, cyclophosphamide, doxorubicin, actinomy cin D, the nitrosoureas and dacarbazine [3][4][5][6][7], Pro phylactic irradiation of the brain with intrathecal metho trexate is seldom recommended [3]. At the National Cancer Institute, 89% of patients (mainly children) treated for primary Ewing sarcoma remained alive 30 months after completion of treatment and 70% of these patients are tumor-free [8].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Ewing Sarcoma: Its Course and Treatment in 50 Adult Patients

et al. 1980

View full text Add to dashboard Cite

34 patients were treated for Ewing sarcoma with primary presentation. There were 10 females and 24 males with average age of 21 years (range 16–36 years). These patients received radiotherapy ( > 5,000 R) to the primary site and combination chemotherapy with vincristine, cyclophosphamide, doxorubicin and actino-mycin D. Of 19 patients with primary presentation in an extremity, 12 remain alive at 29 months without clinical evidence of tumor (63%); 2 patients are alive with relapse. All 10 patients with primary presentation in the pelvis died despite vigorous treatment. 3 patients are alive out of 5 patients with primary presentation in chest or abdominal wall or axilla but only 1 patient remained tumor-free. Of the entire group of 34 patients, 12 remained tumor-free at 27 months (35%). 2 relapsed patients were rendered surgically tumor-free and receive further treatment. 20 patients died or are receiving treatment for advancing disease. 16 patients were treated for locally recurrent (1 patient) or metastatic (15 patients) Ewing sarcoma. There were 6 females and 10 males (average age 24.7 years). These patients received palliative radiotherapy and combination chemotherapy with vincristine, cyclophosphamide, doxorubicin, actinomycin D and dacarbazine. At 36 months, 3 patients are alive tumor-free and 1 patient is alive with stable disease. 12 patients died, 2 after temporarily achieving complete remission.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ewing Sarcoma: Its Course and Treatment in 50 Adult Patients

et al. 1980

View full text Add to dashboard Cite

show abstract

“…Richardson et al [18] followed DTH skin tests in patients receiving BCG in combination with various other forms of therapy for Ewing's sarcoma and noted no change apart from PPD conversion associated with BCG therapy. The strain, dose, and method of administration of BCG used were different from those in the present study, and it is not possible to determine which factor or factors explain(s) the absence of depression of skin test reactivity in their study.…”

Section: Discussionmentioning

confidence: 98%

Immunologic function during adjuvant BCG immunotherapy for malignant melanoma: Induction of anergy

Coates

Klopp

Zarling

et al. 1979

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“High‐affinity” t‐cell rosettes: The effects of clinical manipulations and potential prognostic significance

Weese¹,

West²,

Herberman³

et al. 1980

Journal of Surgical Oncology

View full text Add to dashboard Cite

Incubation of blood mononuclear cells with sheep erythrocytes at 29OC identifies "high-affinity'' rosette-forming T-cells (RFC). The proportion o f highaffinity RFC was more frequently depressed in patients with cancer than the total number of RFC identified under optimal rosetting conditions. Our purpose was to determine the effect of chemotherapy and/or immunotherapy on the level of RFC and t o determine whether trends in serial values had prognostic significance.Two hundred thirty-seven of 270 normal individuals tested had 29OC RFC levels greater than or equal t o 47%, while 21 of 41 untreated cancer patients had higher levels. Cancer patients with depressed 29OC RFC usually normalized within four weeks of operation. Serial studies of 29°C RFC were performed on 32 stage I and I1 lung cancer patients. Eight patients have developed recurrent tumor. We noted a pattern of falling rosette values (two or more consecutive values within normal limits followed by two consecutive depressed values) in five of these patients an average of five months before clinical relapse. Fifteen patients who have remained disease free either maintained normal levels of rosettes or increased into the normal range. Four of 13 (3 1%) stage I and four of nine (44%) stage I1 breast cancer patients had depressed rosette levels preoperatively. In seven stage I1 patients with no further therapy after mastectomy, only t w o of 27 serial tests showed low RFC. Twenty-six stage I1 patients receiving L-phenylalanine mustard (L-PAM) therapy after mastectomy were depressed in 18 of 90From the

show abstract

Immunologic monitoring and immunotherapy in Ewing's sarcoma

Cited by 3 publications

References 20 publications

Ewing Sarcoma: Its Course and Treatment in 50 Adult Patients

Ewing Sarcoma: Its Course and Treatment in 50 Adult Patients

Immunologic function during adjuvant BCG immunotherapy for malignant melanoma: Induction of anergy

“High‐affinity” t‐cell rosettes: The effects of clinical manipulations and potential prognostic significance

Contact Info

Product

Resources

About